%PDF-1.4
%
74 0 obj
<>
endobj
71 0 obj
<>
endobj
132 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-07T11:43:48Z
2024-03-28T23:16:48-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T23:16:48-07:00
application/pdf
Heather
991343.january
uuid:88e0c7ef-1dd2-11b2-0a00-290a275dc400
uuid:88e0c7f1-1dd2-11b2-0a00-810000000000
endstream
endobj
60 0 obj
<>
endobj
61 0 obj
<>
endobj
75 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 38 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 40 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 42 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 44 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 46 0 R/Type/Page>>
endobj
18 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 48 0 R/Type/Page>>
endobj
21 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 50 0 R/Type/Page>>
endobj
24 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 52 0 R/Type/Page>>
endobj
27 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 54 0 R/Type/Page>>
endobj
166 0 obj
[170 0 R]
endobj
167 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2001; 28:1)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(164)Tj
ET
0 0 0 0 k
/GS0 gs
103.27 59.75 407.5 -10.83 re
f*
0.5 w
103.27 59.75 407.5 -10.83 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 57 714.5293 Tm
[(29.)-875.1 (Philbin EF)79.7 (, Grof)17.7 (f GD, Ries MD, Miller )17.7 (TE. Cardiovascular fitness)]TJ
2.175 -1.25 Td
[(and health in patients with end-stage osteoarthritis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw 0 -1.25 TD
(1995;38:799-805.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(30.)-875.1 (Fransen M, Mar)17.7 (giotta E, Crosbie J, Edmonds J. )54.8 (A)-220.1 (revised group)]TJ
2.175 -1.25 Td
(exercise program for osteoarthritis of the knee. Physiotherapy Res)Tj
T*
(Int 1997;2:30-41.)Tj
-2.175 -1.25 Td
[(31.)-875.1 (Altman R, )54.8 (Asch E, Bloch D, et al. Development of criteria for the)]TJ
2.175 -1.25 Td
(classification and reporting of osteoarthritis. Classification of)Tj
T*
[(osteoarthritis of the knee. )54.8 (Arthritis Rheum 1986;29:1039-49.)]TJ
-2.175 -1.25 Td
[(32.)-875.1 (Buckland-W)39.7 (right J, Macfarlane D, )17.7 (W)39.8 (illiams S, )17.7 (W)79.9 (ard R. )54.8 (Accuracy)]TJ
2.175 -1.25 Td
(and precision of joint space width measurements in standard and)Tj
T*
[(macroradiographs of osteoarthritic knees. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(1995;54:872-80.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(33.)-875.1 (Buckland-W)39.7 (right C. Protocols for precise radio-anatomical)]TJ
2.175 -1.25 Td
(positioning of the tibiofemoral and patellofemoral compartments of)Tj
T*
(the knee. Osteoarthritis Cart 1995;3:71-80.)Tj
-2.175 -1.25 Td
[(34.)-875.1 (Mazzuca S. Plain radiography in the evaluation of knee)]TJ
2.175 -1.25 Td
(osteoarthritis. Curr Opin Rheumatol 1997;9:263-7.)Tj
-2.175 -1.25 Td
[(35.)-875.1 (Bellamy N, Buchanan )17.7 (WW)91.7 (, Goldsmith CH, Campbell J, Stitt L)73.9 (W)91.9 (.)]TJ
2.175 -1.25 Td
[(V)110.8 (alidation study of )17.7 (WOMAC: )54.8 (A)-220.1 (health status instrument for mea-)]TJ
T*
(suring clinically important patient relevant outcomes to)Tj
T*
(antirheumatic drug therapy in patients with osteoarthritis of the hip)Tj
T*
(or knee. J Rheumatol 1988;15:1833-40.)Tj
-2.175 -1.25 Td
[(36.)-875.1 (W)79.9 (are J, Snow K, Kosinski M, et al. SF-36 Health Survey: manual)]TJ
2.175 -1.25 Td
[(and interpretation guide. Boston: )17.7 (The Health Institute, New)]TJ
T*
(England Medical Center; 1993.)Tj
-2.175 -1.25 Td
[(37.)-875.1 (W)79.9 (are J, Sherbourne D. )17.7 (The MOS 36-item Short-Form Health)]TJ
2.175 -1.25 Td
(Survey \(SF-36\): I. Conceptual framework and item selection. Med)Tj
T*
(Care 1992;30:473-83.)Tj
-2.175 -1.25 Td
[(38.)-875.1 (Kosinski M, Keller SD, )17.7 (W)79.9 (are JE, Hatoum HT)73.9 (, Kong SX. )17.7 (The SF-)]TJ
2.175 -1.25 Td
(36 Health Survey as a generic outcome measure in clinical trials of)Tj
T*
(patients with osteoarthritis and rheumatoid arthritis: relative)Tj
T*
(validity of scales in relation to clinical measures of arthritis)Tj
T*
[(severity)64.8 (. Med Care 1999;37:MS23-39.)]TJ
-2.175 -1.25 Td
[(39.)-875.1 (Kosinski M, Keller SD, Hatoum HT)73.9 (, Kong SX, )17.7 (W)79.9 (are JE. )17.7 (The SF-)]TJ
2.175 -1.25 Td
(36 Health Survey as a generic outcome measure in clinical trials of)Tj
T*
(patients with osteoarthritis and rheumatoid arthritis: tests of data)Tj
T*
[(quality)64.8 (, scaling assumptions and score reliability)64.8 (. Med Care)]TJ
0 Tc 0 Tw T*
(1999;37:MS10-22.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(40.)-875.1 (W)79.9 (are JE, Kosinski M, Bayliss MS, McHorney CA, Rogers )17.7 (WH,)]TJ
2.175 -1.25 Td
[(Raczek )54.8 (A. Comparison of methods for the scoring and statistical)]TJ
T*
(analysis of SF-36 health profile and summary measures: summary)Tj
T*
[(of results from the Medical Outcomes Study)64.8 (. Med Care)]TJ
0 Tc 0 Tw T*
(1995;33:AS264-79.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(41.)-875.1 (Jenkinson C, Layte R, Lawrence K. Development and testing of the)]TJ
2.175 -1.25 Td
(Medical Outcomes Study 36-Item Short Form Health Survey)Tj
T*
(summary scale scores in the United Kingdom. Med Care)Tj
0 Tc 0 Tw T*
(1997;35:410-6.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(42.)-875.1 (Fransen M, Heussler J, Mar)17.7 (giotta E, Edmonds J. Quantitative gait)]TJ
2.175 -1.25 Td
(analysis \321 comparison of rheumatoid arthritic and non-arthritic)Tj
T*
[(subjects. )54.8 (Australian J Physiotherapy 1994;40:191-9.)]TJ
-2.175 -1.25 Td
[(43.)-875.1 (Fransen M, Crosbie J, Edmonds J. Reliability of gait measurements)]TJ
2.175 -1.25 Td
[(in people with osteoarthritis of the knee. Phys )17.7 (Ther 1997;)]TJ
0 Tc 0 Tw T*
(77:944-53.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(44.)-875.1 (Bellamy N, Carette S, Ford PM, et al. Osteoarthritis antirheumatic)]TJ
2.175 -1.25 Td
[(drug trials. II. )17.7 (T)69.9 (ables for calculating sample size for clinical trials. )]TJ
T*
(J Rheumatol 1992;19:444-50.)Tj
30.825 70 Td
[(45.)-875.1 (W)79.9 (are JE, Kosinski M, Keller SD. SF-36 Physical and Mental)]TJ
2.175 -1.25 Td
[(Health Summary Scales: )54.8 (A)-220.1 (User)-37 (\325)55.1 (s Manual. Boston: )17.7 (The Health)]TJ
T*
(Institute, New England Medical Center; 1994.)Tj
-2.175 -1.25 Td
[(46.)-875.1 (Australian Bureau of Statistics. National Health Survey)64.8 (. SF-36)]TJ
2.175 -1.25 Td
[(population norms. Belconnen: )54.8 (Australian Bureau of Statistics;)]TJ
0 Tc 0 Tw T*
(1995.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(47.)-875.1 (Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in)]TJ
2.175 -1.25 Td
(therapeutic trials. J Chronic Dis 1967;20:637-48.)Tj
-2.175 -1.25 Td
[(48.)-875.1 (Andrews )54.8 (A)79.8 (W)91.8 (, )17.7 (Thomas MW)91.7 (, Bohannon R)54.8 (W)91.8 (. Normative values for)]TJ
2.175 -1.25 Td
(isometric muscle force measurements obtained with hand-held)Tj
T*
[(dynamometers. Phys )17.7 (Ther 1996;76:248-59.)]TJ
-2.175 -1.25 Td
[(49.)-875.1 (Skelton DA, Grieg CA, Davies JM, )36.8 (Y)99.8 (oung )54.8 (A. Strength, power and)]TJ
2.175 -1.25 Td
[(related functional ability of healthy people aged 65-89 years. )54.8 (Age)]TJ
0 Tc T*
(Ageing 1994;23:371-7.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(50.)-875.1 (Buchner DM, Larson EB, )17.7 (W)79.9 (agner EH, Koepsell )17.7 (TD, de Lateur BJ.)]TJ
2.175 -1.25 Td
(Evidence for a non-linear relationship between leg strength and gait)Tj
0 Tc -0.02991 Tw T*
[(speed. Age Ageing )-54.9 (1996;25:386-91.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(51.)-875.1 (Ferrucci L, Guralnik JM, Buchner D, et al. Departures from)]TJ
2.175 -1.25 Td
(linearity in the relationship between measures of muscular strength)Tj
T*
[(and physical performance of the lower extremities: the )17.7 (W)79.9 (omen\325)54.8 (s)]TJ
T*
[(Health and )54.8 (Aging Study)64.8 (. J Gerontol 1997;52A:M275-85.)]TJ
-2.175 -1.25 Td
[(52.)-875.1 (Sharma L, Lou C, Felson DT)73.9 (, et al. Laxity in healthy and)]TJ
2.175 -1.25 Td
[(osteoarthritis knees. )54.8 (Arthritis Rheum 1999;42:861-70.)]TJ
-2.175 -1.25 Td
[(53.)-875.1 (Sharma L, Hayes KW)91.7 (, Felson DT)73.9 (, et al. Does laxity alter the)]TJ
2.175 -1.25 Td
(relationship between strength and physical function in knee)Tj
T*
[(osteoarthritis? )54.8 (Arthritis Rheum 1999;42:25-32.)]TJ
-2.175 -1.25 Td
[(54.)-875.1 (Buchner DM. Understanding variability in studies of strength)]TJ
2.175 -1.25 Td
[(training in older adults: a meta-analytic perspective. )17.7 (T)69.9 (op Geriatr)]TJ
T*
(Rehabil 1993;8:1-21.)Tj
-2.175 -1.25 Td
[(55.)-875.1 (Pai )36.8 (Y)110.8 (-C, R)39.7 (ymer )17.7 (WZ, Chang R)54.8 (W)91.9 (, Sharma L. Ef)17.7 (fect of age and)]TJ
2.175 -1.25 Td
[(osteoarthritis on knee proprioception. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1997;40:2260-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(56.)-875.1 (Jef)17.7 (ferson RJ, Collins JJ, )17.7 (Whittle MW)91.7 (, Radin EL, O\325Connor JJ. )17.7 (The)]TJ
2.175 -1.25 Td
(role of the quadriceps in controlling impulsive forces around the)Tj
T*
(heel. J Engineer Med 1990;204:21-8.)Tj
-2.175 -1.25 Td
[(57.)-875.1 (Schnitzer )17.7 (TJ, Popovich JM, )54.8 (Andersson GB, )54.8 (Andriacchi )17.7 (TP)110.8 (. Ef)17.7 (fect)]TJ
2.175 -1.25 Td
(of piroxicam on gait in patients with osteoarthritis of the knee.)Tj
T*
(Arthritis Rheum 1993;36:1207-13.)Tj
-2.175 -1.25 Td
[(58.)-875.1 (Hochber)17.7 (g MC, Perlmutter DL, Hudson JI, )54.8 (Altman R. Preferences in)]TJ
2.175 -1.25 Td
(the management of osteoarthritis of the hip and knee: results of a)Tj
T*
(survey of community-based rheumatologists in the United States.)Tj
T*
(Arthritis Care Res 1996;9:170-6.)Tj
-2.175 -1.25 Td
[(59.)-875.1 (Messieh SS, Fowler PJ, Munro )17.7 (T)74 (.)-0.1 ( )54.8 (Anteroposterior radiographs of)]TJ
2.175 -1.25 Td
[(the osteoarthritis knee. J Bone Joint Sur)17.7 (g \(Br\) 1990;72-B:639-40.)]TJ
-2.175 -1.25 Td
[(60.)-875.1 (Lethbridge-Cejku M, Scott )17.7 (WW)91.7 (, Reichle R, et al. )54.8 (Association of)]TJ
2.175 -1.25 Td
(radiographic features of osteoarthritis of the knee with knee pain:)Tj
T*
[(data from the Baltimore Longitudinal Study of )54.8 (Aging. )54.8 (Arthritis)]TJ
T*
(Care Res 1995;8:182-8.)Tj
-2.175 -1.25 Td
[(61.)-875.1 (Dekker J, Boot B, )17.7 (V)110.8 (an der )17.7 (W)79.9 (oude L, Bijlsma J. Pain and disability)]TJ
2.175 -1.25 Td
(in osteoarthritis: a review of biobehavioural mechanisms. J Behav)Tj
0 Tc T*
(Med 1992;15:189-212.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(62.)-875.1 (T)35 (urk DC, Okifuji )54.8 (A. )54.8 (Assessment of patients\325)-201.1 (reporting of pain: an)]TJ
2.175 -1.25 Td
(integrated perspective. Lancet 1999;353:1784-8.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
106.328 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
54 0 obj
<>stream
8;Z\6JSsR'#ikr7OPdV9)JkV!Ui/kL3iQe=CJu.e(oQf*^%Pg$2>b,_](:+*f=eZn
eeZ-5h:13XFh\u%gX3pH]k,h=6B?I:ZYA^l`>5+A#UM/CY*db)N4&SY:kJ2D[B(Va
8KPWt;iSp@YIhcHG*4(rl37K$)9]>j";T^F%gd[TBj8MA6Sd),`o`G.PSqP7rj=Aa
Rjf?I!IeT)_`P#2*%a<4G%afdA/(cV#D9k(\tS&gnP2Ea][6tV]a>1B,)JE*GjEX5G,TT_4q(=2bI^sqBJ2&J3&k7265
6A^O5*]97VlBu[j8;\hH>D_jnK.0ufUuZ%uD[m(O;%4/Cl_5R?#MirQ6_+q!HA%=4
MD:I8P3LX3a!Z@UK_&kgL[_C\/&b1CK,a33YB!;mk[Tfou\*5-J_WE,l4D#nOe%o;K\03po4bi):%(,U
ZLKK^VDTOL4OHMI2OCd"SimQHaK,9Cm2'@hAWP!Ts^KS&(^ogE\+]ZZ)*
Af*+M-<,&`D$2A;%LbeqJd7,&2;$Xj*?:4i#,OTISoe\+?pnhrW6o1=jo7Xp9V[YU
%)VU1[HEo%dq/ZN#:2Rhblun'Q<653m8#=5gHWsD[F\`+q/lYPcKqjnnPje+H->C+
X&2*i56Cli+XFu~>
endstream
endobj
58 0 obj
[/Indexed/DeviceRGB 255 57 0 R]
endobj
57 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
77 0 obj
<>
endobj
82 0 obj
<>
endobj
113 0 obj
<>
endobj
137 0 obj
<>
endobj
81 0 obj
<>
endobj
104 0 obj
<>stream
H|UTIITҐdeP030#OH
(_EEP::?{VXm9{vLWկ߭w_W81pYq*VAPO34X㌍ #%+MNS#3#wQLJeg$MyPo,Jeeխ.~&ūvDs.˖.rK&2gfRUNת5ZMB/{':yRj'*W
>^UG5>*FU=WxT*EJ;paq1O`f"l[a+0i0,a1 mfdIl5?xz4&Mcqr>y;mr?fxq))ON=7մyӪ
z,<3_n~d,fZZ챨swDD3IE<2gf`geom+$'i!IZ;Y::zw6
;Co0g)S |};eM(4` [r!Nxmcb/s@
pVyu5"maվePs}nYGykO7-ba
Eo[OG'D_b]* |m?Dr6~sZ?%./CC;קdyd/&/2(Ƌ,%iuoؙJ˒+;F-Hc thq؈w>%*ZD!G0a-Hi'I)C+%(H$B/HyJUz)f
J$0"w rDrDϓ
Y0|Ʃʤ!5J:+**WWy09U
wt*9^ȏ=udDq|:mژD騲
ba '"۲O54]o0NI:lL(i,Ӿܫms@lY"Y"_ ۟yH-aS?8~tȇ'<,F(&6ZXSܤ f6{`Cqa5\Tc)0ԎYU0[Ur༭G7o`y"L u(PCFlU(6 G<6d+db
MIr; 5b[~ 3C~bw S}WCT
6O,Oȗ?\dm V.CDiy&y8~2ys
-j Gʻ^(um7iFbV,']ٽAf/'NܝsGApQ,n;;oJurg coċ1HŞCAp{?`oQ0L=1!`-oFҎbipQya~ r8/}iub&_T8ea.{f\@52ùQF5̆T\rd
S#{b$g0!``
(e@|ydC~>E܉'_^z~M-1σ7jm*eW52YS\s*k;YzmG
cVD=T^~An^_T&Uv[m"
|T6%
r3+n{voTTew ^ƚ.#OS^]w%}mnuaX n
^2cUWe`vɾgqw՟|JŁn yKWd;Bָ,C<46$Dvq@.aQ!mVll.B&O&Q:0=l=Dd t2*uu6Nimc`xvxtG^&>jB%xQ*c&:,@<39H/.s~d}/T/B
]QM]Y=R:!G'>1Z(>RHSH.AOZEZ3Kt}g$T'JwvH8&c\R}c lhi:sYHBVM7nWdS0~j0*ZtT6j 8l\KxCT)۶01[PUe-UT+*;}YfTzgrE"Ht`](8!O YS
щJP`\IlP$JCALG?2N5D+5}'xr6谐Onoc-"ik@4鱣B:`';ٱ%j:dihKi'?2{;ẎĬ\~63xa'o|%*[_̰GSB9U3i A&&yzH@FD˕30Z2z]b{4FmR^BQڡ첿;lV09jP̰?yq`e)[
P["F9^JY/>cᄏDfj.`K*\n0iAw\4b![_F4;\,
>knRck:,05XF^Jhɝe܌4mjtd&
N ;[(T$W3!MJH$VSmë/
/~Ks^<31WB(~daa33 vx֦5s؉_9MSm~m^#M^j7hUVZӴܪpm3RfiDhȜ+8ޅ0Е+I$G6`Ύ]nTDr?,CXbS>-mqfƢ_Zǩ!=Gt8g>|WSX|D{>1FzsؤȎӉa!"qþEJo1k>V9^ХRZ=W= ;'gLr,ܵNC_k
>n0m#p)KS;0
[}cw N7;@|~!ef[5
Cϰmeza"mYJ{~ч"q@T-JM'*#r
V *6:+2"k1_cVöh
ه>;ݖ]8`+v%(G9ƅ3؟(-fVAMkxwYIGn^s缒I[>+$~lT?g5~CX"nS+?vl&|oeF
gyg*}7n<<=BDvN
8 c:.;`no%zL@b,t3N}2˘gty\9e's5y'.xRIώ˟~%.T{ٕ${IV'[nFi ~kLIRXNS'P
s7֜SH)̍;tD6/tӢ./*0%W._¶Qz(.@!N t}=&!P"IYvUnqQw*\OJMӹ "io2Q#N#2WRn>)0%U7%TW+7!->䴑6(}ݩq5'6!&Z"BV.b֓s"̲EAOei\؇˖1LUU&\rTPr:-t9Y k̆
M^n-gY4HgW]T & r?V8rH>M/I=)8cU.5;J9)9ƭǁ